ABSTRACT
the coding region or promoter leading to the hypothesis that there is another, as 48 yet unidentified mechanism of alginate regulation in this clinical strain.
49

INTRODUCTION
phenotype is a result of the production of a complex polysaccharide called 71 alginate (16). algT/U, codes for a sigma factor able to bind to RNA polymerase (RNAP), guiding 85 it to transcribe the genes necessary for alginate production (31, 32).
86
Under normal circumstances, P. aeruginosa is non-mucoid, as is the case with the 87 prototypic reference strain, PAO1 (33). Upon colonizing the CF lung, P. aeruginosa 88 must confront the host immune system and antibiotics. The typical response is to 89 convert to a mucoid phenotype by producing alginate. This is commonly 90 accomplished by mutating mucA which codes for the anti-sigma factor to AlgT/U 91 7 (22). The potential issue with using PDO300 is that laboratory strains cannot 112 faithfully mirror the real-world pathogenesis of a clinical isolate (39) .
113
The present study was undertaken to map the location of second-site mutations 114 in a clinical isolate. The strain utilized is P. aeruginosa 2192 which was isolated from 115 a CF patient in Boston who passed away from the infection (40) 
Bacterial Strains
124
The P. aeruginosa and Escherichia coli strains used in this study are listed in 125   Table 1 . The E. coli strains were grown on Luria-Bertani (LB) media supplemented 126 with tetracycline (Tc) at 20 μg/ml and ampicillin (Ap) at 50 μg/ml. Pseudomonas 127 aeruginosa strains were grown on LB or LB/PIA plates, which is a 1:1 mixture of LB
128
and Pseudomonas isolation agar. These were supplemented with Tc at 100 μg/ml 129 or carbenicillin (Cb) at 150 μg/ml when appropriate.
130
Isolation of sap mutants
131
The parent strain used to isolate suppressor of alginate production (sap) were selected and inoculated into separate tubes containing 5 ml of LB nutrient 136 broth. These were serially cultured at 25°C without aeration for two weeks.
137
Dilutions of each of the 12 cultures were plated daily for single colonies. The 127 138 sap mutant colonies were frozen in 1:1 culture/skim milk at -80°C for further analysis 139 (Table 1) . At the end of two weeks, all sap mutants were re-streaked on to LB/PIA 140 plates and incubated at 37°C for 24 hours followed by 25°C for 24 more hours.
141
Only the 41 sap mutants that maintained a non-mucoid phenotype after 48 hours 142 during this secondary screening were used in subsequent analyses. complemented by pCD100 containing the whole algT/U operon. These were also 210 complemented by pJG293 containing algT/U alone (Table 1) .
211
The mucoid phenotype was restored in 11 sap mutants (17%) when 212 complemented by mucP. Similarly, algO successfully complemented four (10%) 213 of the mutants that were also complemented by mucP.
214
Two sap mutants, sap8 and sap20, were not complemented by any of the 215 previously identified genes. When pCD100 (37) was introduced, the two mutants failed to grow. In the presence of pJG293 (37), the strains grew and were 217 nonmucoid.
218
Sequencing mucA 219 P. aeruginosa 2192 contains a mutation in the anti-sigma factor mucA which 220 results in constitutive alginate production. To determine the exact mutation, the 221 mucA of P. aeruginosa 2192 was aligned with PAO1, the common reference strain 222 which has no mutation, and PDO300, the laboratory-generated strain containing Non-mucoid variants of P. aeruginosa 2192 were isolated in the same way as 252 previous studies that utilized PDO300 as the parent strain (37). Studies using 253 PDO300 saw a 90% reversion to sap mutants after just 48 hours of culturing at 25°C 254 without aeration (37). In contrast, PA2192 took two weeks under the same 255 conditions to yield even a 3.8% reversion that could be utilized in further analyses.
256
This extended time needed to isolate non-mucoid variants is unique to P. The mucA sequence alignment of the non-mucoid variants revealed that they 288 maintain the mucA180 allele. Thus, the loss of alginate production is not the result 289 of a true reversion that has restored the function of MucA, but is due to a second-290 site mutation, as was hypothesized.
291
Complementation assays have shown that a majority (68%) of the second-site 
295
This suggests that there may be a novel mechanism of alginate regulation in P. This study also found that mucP was able to restore the Alg + phenotype of 17% of 301 the non-mucoid variants, indicating that second-site mutations in mucP were the 302 second most common mode of alginate repression in P. aeruginosa 2192. The 303 third most common second-site mutation in alginate suppression is in algO (10%).
304
Moreover, all the non-mucoid variants that were complemented by algO were 305 also complemented by mucP, suggesting that algO mutations can be bypassed These two mutants prove fatal when the algT/U operon was introduced on 322 pCD100. It is hypothesized that either these two do not take up the plasmid for some reason, and thus are killed on the selective media, or the novel mutation,
324
which is yet to be identified, will be able to explain this highly unusual 325 phenomenon.
326
Conclusion
327
Care for CF patients over the last thirty years has dramatically improved. Life 328 expectancy has risen from 18 years in the 1980's to nearly 50 today (9). P. The present study sought to contribute to this end by investigating regulatory 335 genes involved in the mucoid to non-mucoid reversion of the clinical strain P. 
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